Group 1 - Apollomics Inc. is a late-stage clinical biopharmaceutical company focused on developing oncology drug candidates for difficult-to-treat and treatment-resistant cancers [1][2] - The company will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, with a presentation available on demand starting September 9, 2024, at 7:00 am ET [1] - Key presenters include Guo-Liang Yu, PhD, Chairman and CEO, and Matthew Plunkett, PhD, CFO, with opportunities for virtual one-on-one meetings for interested investors [1] Group 2 - Apollomics' lead product candidate is vebreltinib, a selective c-Met inhibitor for non-small cell lung cancer, currently in a Phase 2 multicohort global clinical trial [2] - The company is also developing uproleselan, an E-Selectin antagonist, which is in a Phase 3 clinical trial in China for treating acute myeloid leukemia and other hematologic cancers [2]
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference